Optimizing Integration of Precision Therapy Into the Treatment of HER2-Low, HR-Positive, and Triple Negative Breast Cancer: A Focus on HER2- Targeted and TROP-2–Targeted Therapy

Learn how the experts integrate precision therapy into the treatment algorithm for patients with HER2-low, HR-positive and triple-negative breast cancer in this program centered around a dynamic live symposium at ASCO 2023. Download slides, watch the on-demand webcast, and read an expert-authored commentary summarizing the key learning points from the live symposium for use in your clinic.

Share

Program Content

No activities added yet

No activities added yet

No activities added yet

Provided by

ProCE Banner

Provided by Clinical Care Options, LLC.

Supporters

Supported by educational grants from AstraZeneca, Daiichi Sankyo, Inc., and Gilead Sciences, Inc.

AstraZeneca

Daiichi Sankyo

Gilead Sciences, Inc.